TPST - Tempest Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TPST is currently covered by 3 analysts with an average price target of $14.58. This is a potential upside of $7.33 (101.1%) from yesterday's end of day stock price of $7.25.

Tempest Therapeutics's activity chart (see below) currently has 5 price targets and 25 ratings on display. The stock rating distribution of TPST is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50% with an average time for these price targets to be met of 127.67 days.

Highest price target for TPST is $16, Lowest price target is $16, average price target is $12.

Most recent stock forecast was given by JOSEPH PANTGINIS from HC WAINWRIGHT on 10-Apr-2025. First documented stock forecast 06-Jul-2021.

Best performing analysts who are covering TPST - Tempest Therapeutics:

Edward Tenthoff Aydin Huseynov Joseph Pantginis

Currently out of the existing stock ratings of TPST, 15 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$16

$9.78 (157.23%)

$16

6 days ago
(10-Apr-2025)

0/4 (0%)

$10.14 (173.04%)

Buy

$8

5 months 3 days ago
(13-Nov-2024)

2/4 (50%)

$5.97 (294.09%)

104

Buy

$8

$1.78 (28.62%)

$8

1 years 11 months 19 days ago
(28-Apr-2023)

2/2 (100%)

$5.88 (277.36%)

279

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TPST (Tempest Therapeutics) average time for price targets to be met?

On average it took 127.67 days on average for the stock forecasts to be realized with a an average price target met ratio 50

Which analyst has the current highest performing score on TPST (Tempest Therapeutics) with a proven track record?

EDWARD TENTHOFF

Which analyst has the current lower performing score on TPST (Tempest Therapeutics) with a proven track record?

JOSEPH PANTGINIS

Which analyst has the most public recommendations on TPST (Tempest Therapeutics)?

Edward Tenthoff works at PIPER SANDLER and has 5 price targets and 4 ratings on TPST

Which analyst is the currently most bullish on TPST (Tempest Therapeutics)?

Joseph Pantginis with highest potential upside - $9.78

Which analyst is the currently most reserved on TPST (Tempest Therapeutics)?

Edward Tenthoff with lowest potential downside - -$0

Tempest Therapeutics in the News

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC Received FDA “Study May Proceed” letter for TPST-1495 in a Phase 2 trial...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?